Participants in studies used as basis for medicare decisions differ from beneficiaries

Cardiovascular disease is the leading cause of death and disability among Medicare beneficiaries, according to background information in the article; expenses for this condition exceed those for any other. “Because Medicare expenditures continue to increase rapidly, it is necessary that coverage decisions be based on data most likely to maximize value and optimize outcomes for Medicare beneficiaries,” the authors write. An independent panel of physicians and other professionals advises the Centers for Medicare and Medicaid Services (CMS) on medical technologies. Panelists review technology assessments prepared for each new medical product or service and then vote on the quality of evidence for health benefits.

Sanket S. Dhruva, B.A., and Rita F. Redberg, M.D., M.Sc., of the University of California at San Francisco School of Medicine performed a meta-analysis of all trials included in technology assessments considered by the CMS advisory panel between 1998 and 2006. For the panel’s six meetings, 141 studies with a total of 40,009 participants were analyzed.

Compared with Medicare beneficiaries, clinical trial participants were an average of 60.1 years vs. 74.7, 75.4 percent vs. 41.8 percent male and 60 percent vs. zero lived in countries outside the United States. “The trials are conducted mostly in younger, healthier, male, non–U.S. populations,” the authors write. “Medicare beneficiaries, on the other hand, are mostly older women with comorbid [co-occurring] conditions. The clinical trials primarily relied on to inform national coverage decisions simply do not reflect the Medicare patient population. Compounding this problem, data frequently are not reported by age, sex and race.”

Elderly people and women are the most likely to be affected by these disparities and should be included in more clinical trials, the authors note. “The Food and Drug Administration already requests sex-specific data for new drug applications; it certainly would be consistent, and logical, for the CMS to require direct evidence of benefit in the coverage process. Alternatively, the CMS could issue a coverage decision with a requirement that continued coverage after a specified period depends on additional subgroup data, a variation of the newly introduced ‘coverage with evidence development’ initiative,” they write. “Closer linkage of evidence to coverage would promote better value and improved outcomes for the rapidly growing and underrepresented population of Medicare beneficiaries.”

Commentary: Clinical Trial Results Cannot Always Be Generalized

The results of randomized clinical trials are most directly applied to populations of patients similar to those who participated in the study, write Noel S. Weiss, M.D., Dr.P.H., and colleagues at the University of Washington, Seattle, in an accompanying commentary.

“However, as Dhruva and Redberg illustrate in this issue of the Archives, the demographic profile of a trial’s participants and the medical care environment in which the trial is conducted may differ considerably from the target population and practice context in which the trial’s findings are later used to guide clinical decision making and policy,” the authors write.

“Although the measured effect of a particular therapy on a health outcome in the study population included in a given trial will, in many instances, closely reflect the effect of that intervention on the corresponding outcome in other settings, this extrapolation should not be made reflexively,” they conclude.

Source: JAMA and Archives Journals

PET confirmed as valuable cancer diagnostic and disease-staging tool
The recent release of data by the National Oncologic PET Registry (NOPR) showing that positron emission tomography (PET) produced scans revealing disease at a molecular level, which then caused physicians to change treatment plans for more than one-third of participating patients, has corroborated decades of nuclear medicine research.
Study shows cholesterol-lowering power of dietitian visits
Worried about your cholesterol? You may want to schedule a few appointments with a registered dietitian, to get some sound advice about how to shape up your eating habits, according to a new national study led by University of Michigan Health System researchers.
Cancer caught early with colonoscopies
Medicare's extension of coverage for colonoscopies led to a significant increase in the number of cancers caught early, a U.S. study finds.
Chest pain center accreditation linked with better outcomes in heart attack patients
Hospitals accredited by the Society of Chest Pain Centers (SCPC) have been shown to perform better in the heart attack core measures established by Centers for Medicare and Medicaid Services (CMS) as compared to non-accredited hospitals, according to a national study led by an Emory University researcher.
Savings help the medicine go down
Prescription drug coverage for low income seniors reduces Medicaid
A new study of state-subsidized pharmacy assistance programs showed that providing prescription drug coverage for low-income seniors reduces Medicaid and Medicare costs. Moreover, needy seniors enrolled in the programs were able to cut their dose skimping and nursing home admissions in half, according to the Brandeis University research.
Anti-rejection drug may increase risk of diabetes after kidney transplant
For patients undergoing kidney transplantation, treatment with the anti-rejection drug sirolimus may lead to an increased risk of diabetes, reports a study in the July Journal of the American Society of Nephrology (JASN).
More patients with drug-coated cardiac stents survive, avoid costly follow-up procedures
The more than ten million Americans who’ve received drug-eluting stents to open their blocked coronary arteries have a bright future, according to new research from the University of Pennsylvania School of Medicine.
Hospitals that mostly treat Medicaid patients have made smaller quality performance gains
Hospitals that predominantly treat poor and underserved patients (often referred to as safety-net hospitals) have made smaller improvements in quality performance measures in recent years compared to hospitals that do not primarily serve this patient population, according to a study in the May 14 issue of JAMA.

Participants in studies used as basis for medicare decisions differ from beneficiaries

Related stories:

News discussion: